Brokerages Set uniQure N.V. (NASDAQ:QURE) Price Target at $65.00

uniQure N.V. (NASDAQ:QURE) has earned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $65.00.

A number of equities research analysts have commented on the company. Mizuho increased their target price on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research report on Wednesday, June 17th. Royal Bank Of Canada increased their price objective on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Leerink Partners lifted their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Finally, Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a research note on Wednesday, July 29th.

Insider Activity

In other news, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director owned 43,254 shares of the company’s stock, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares in the company, valued at $23,448,291.32. The trade was a 3.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 388,229 shares of company stock valued at $16,817,099. 4.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Torren Management LLC purchased a new position in uniQure during the fourth quarter worth about $28,000. IFP Advisors Inc purchased a new stake in uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure during the 4th quarter valued at about $48,000. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

NASDAQ:QURE opened at $46.42 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The firm has a market cap of $3.22 billion, a price-to-earnings ratio of -11.58 and a beta of 0.93. The firm’s fifty day moving average price is $39.41 and its 200 day moving average price is $27.07. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same quarter in the previous year, the company posted ($0.69) EPS. On average, sell-side analysts expect that uniQure will post -3.74 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.